摘要
目的探讨乳腺增生及乳腺癌组织中雌激素受体（ER）、孕激素受体（PR）的表达差异及其临床意义。方法采用免疫组织化学方法检测68例乳腺增生和168例乳腺癌标本中ER、PR的表达。结果乳腺癌患者ER表达水平明显高于乳腺增生患者（P〈0．05），而PR在两组中的表达差异无统计学意义。绝经后乳腺癌患者ER表达水平中位值为30％，明显高于绝经后乳腺增生患者的10％（P〈0．05），而在绝经前两组患者ER表达水平差异无统计学意义。浸润性小叶癌组织内PR的表达明显高于浸润性导管癌等其他类型，差异有统计学意义（P=0．005）。结论ER、PR的表达能够较好地反映乳腺疾病的病理生物学特征。
Objective To investigate the expression of ER and PR in hyperplasia of mammary glands and breast cancer. Methods The expression of ER and PR in 68 hyperplasia of mammary glands cases and 168 breast cancer cases were quantified by immunohistochemical method. Results The expression of ER in breast cancer（30 %） was significantly higher than that in hyperplasia of mammary glands（10 %）（P 〈0.05） and there was no significant difference in PR between them. The expression of ER in postmenopausal breast cancer was significantly higher than that in postmenopausal hyperplasia of mammary glands （P 〈0.05） and there was no significant difference in ER between two premenopausal groups. The expression of PR in invasive lobular carcinoma was significantly higher than that in invasive duetal carcinoma and other types （P=0.005）. Conclusion The expression of ER and PR may identify the characteristics of patholobiology in breast disease.
出处
《肿瘤研究与临床》
CAS
2010年第3期158-160,共3页
Cancer Research and Clinic
关键词
乳腺增生
乳腺肿瘤
受体
雌激素
受体
孕激素
Hyperplasia of mammary glands
Breast neoplasms
Receptors, estrogen
Receptors, progestin
